Dominic Curran

An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results

Vignesh T. Packiam, Donald L. Lamm, Daniel A. Barocas et al. · Urologic Oncology Seminars and Original Investigations · 2017 · 231 citations

Urology, Open Label, Genitourinary Cancer +7

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study

Thomas Yau, Ahmed O. Kaseb, Ann‐Lii Cheng et al. · ˜The œLancet. Gastroenterology & hepatology · 2024 · 65 citations · Full text

Final Results, Oncology, Hepatology +10

Severe arthritis predicts greater improvements in function following total knee arthroplasty

Oliver D. Stone, Andrew D. Duckworth, Dominic Curran et al. · Knee Surgery Sports Traumatology Arthroscopy · 2015 · 35 citations

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study.

Neeraj Agarwal, Yohann Loriot, Bradley A. McGregor et al. · Journal of Clinical Oncology · 2020 · 32 citations

Pharmacotherapy, Immunotherapeutics, Metronomic Chemotherapy +20

Cabozantinib in combination with atezolizumab in urothelial carcinoma previously treated with platinum-containing chemotherapy: Results from cohort 2 of the COSMIC-021 study.

Sumanta K. Pal, Neeraj Agarwal, Yohann Loriot et al. · Journal of Clinical Oncology · 2020 · 26 citations

Platinum-containing Chemotherapy, Pharmacotherapy, Metronomic Chemotherapy +18